Biomarin, Gilead drug rejections don't signal a change in the FDA's attitude

Biomarin, Gilead drug rejections don't signal a change in the FDA's attitude

STAT Plus: Do surprise drug rejections signal a more conservative FDA? Don’t bet on it

By ADAM FEUERSTEIN

SARAH SILBIGER/GETTY IMAGES

It’s tempting to interpret the FDA's surprise rejections of two drugs this week as an agency-wide downshift. But that would be a mistake.

READ MORE